Baseline characteristics | Not receiving fluconazole | Receiving fluconazole | Pvalue | |
---|---|---|---|---|
(n = 225) | 400 mg/week (n = 392) | 200 mg/day (n = 69) | ||
Gender: Male | 116 (51.6%) | 213 (54.3%) | 49 (71.0%) | 0.016 |
Female | 109 (48.4%) | 179 (45.7%) | 20 (29.0%) | |
Age, years, mean ± SD | 36.0 ± 7.5 | 35.0 ± 7.4 | 34.7 ± 8.03 | 0.200 |
Weight, kg., mean ± SD | 54.9 ± 10.6 | 52.3 ± 10.0 | 51.4 ± 8.7 | 0.008 |
Previous opportunistic infections, patients (%) | ||||
Any major opportunistic infections | 53 (23.6%) | 120 (30.6%) | 24 (34.8%) | 0.368 |
Tuberculosis | 32 (14.2%) | 64 (16.3%) | 17 (24.6%) | 0.124 |
PCP | 31 (13.8%) | 47 (12.0%) | 8 (11.6%) | 0.787 |
Histoplasmosis | 3 (1.3%) | 1 (0.3%) | - | 0.190 |
Penicilliosis | 3 (1.3%) | 0 (0.0%) | - | 0.046 |
Toxoplasmosis | - | 5 (1.3%) | - | 0.151 |
MAC | 2 (0.9%) | 2 (0.5%) | - | 0.669 |
Concurrent medication | ||||
Cotrimoxazole | 176 (78.2%) | 363 (93.3%) | 57 (82.6%) | < 0.001 |
Antituberculous drugs | 47 (20.9%) | 82 (20.9%) | 22 (31.9%) | 0.095 |
Baseline CD4 cell count, cell/mm3, median (IQR) | 85 (21–159) | 18 (7–48) | 16 (5–35) | < 0.001 |
Baseline % CD4, median (IQR) | 7 (2–11) | 2 (1–5) | 2 (1–5) | < 0.001 |
Baseline plasma HIV RNA, | 207,500 | 270,000 | 169,000 | 0.095 |
copies/ml, median (IQR) | (68,375–549,500) | (118,000–545,000) | (76,750–415,000) | |
Baseline AST, U/L, median (IQR) | 31 (23–46.5) | 32 (25–53.2) | 34 (24–53) | 0.358 |
Baseline ALT, U/L, median (IQR) | 23 (17–39) | 28 (17–45) | 32 (17–49.5) | 0.177 |
Baseline TB, mg/dl, median (IQR) | 0.5 (0.4–0.65) | 0.5 (0.4–0.7) | 0.5 (0.4–0.8) | 0.843 |